文献速递脑血管病

卒中后房颤检测的生物标志物:系统综述与荟萃分析

Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2021-09-09

该系统综述与荟萃分析纳入34项队列研究共11569例缺血性卒中/TIA患者,房颤检出率为12.8%。研究识别出与房颤检出相关的临床、心电图和血液生物标志物,包括年龄、性别、合并症、卒中严重程度、P波指标及利钠肽等,可辅助选择心脏监测患者。

要点

  • 年龄、女性、心衰、高血压、缺血性心脏病与卒中后房颤检出风险升高相关。
  • P波离散度、脑钠肽、QTC间期等心电图和血液标志物与房颤检出强相关。
  • 低密度脂蛋白胆固醇和甘油三酯浓度与房颤检出风险降低相关。

核心结论

  • 多模态生物标志物有助于指导缺血性卒中/TIA后心脏监测的患者选择。

研究设计与样本

  • 系统综述与荟萃分析,检索2000年1月15日至2020年1月15日的队列研究,最终纳入34项研究共11569例参与者。

主要发现

  • 34项研究共评估69个变量,其中42个临床、20个心电图和7个血液生物标志物。
  • 与房颤检出风险升高相关的因素包括年龄(OR 3.26,95%CI 2.35-4.54)、女性(OR 1.47,95%CI 1.23-1.77)、心衰史(OR 2.56,95%CI 1.87-3.49)、高血压(OR 1.42,95%CI 1.15-1.75)、缺血性心脏病(OR 1.80,95%CI 1.34-2.42)、较高改良Rankin量表评分(OR 6.13,95%CI 2.93-12.84)、较高NIHSS评分(OR 2.50,95%CI 1.64-3.81)、无显著颈/颅内动脉狭窄(OR 3.23,95%CI 1.14-9.11)、无吸烟(OR 1.93,95%CI 1.48-2.51)、他汀治疗(OR 2.07,95%CI 1.14-3.73)、卒中作为索引诊断(OR 1.59,95%CI 1.17-2.18)、收缩压(OR 1.61,95%CI 1.16-2.22)、静脉溶栓(OR 2.40,95%CI 1.83-3.16)、房室传导阻滞(OR 2.12,95%CI 1.08-4.17)、左心室肥厚(OR 2.21,95%CI 1.03-4.74)、房性期前收缩(OR 3.90,95%CI 1.74-8.74)、最大P波持续时间(OR 3.19,95%CI 1.40-7.25)、PR间期(OR 2.32,95%CI 1.11-4.83)、P波离散度(OR 7.79,95%CI 4.16-14.61)、P波指数(OR 3.44,95%CI 1.87-6.32)、QTC间期(OR 3.68,95%CI 1.63-8.28)、脑钠肽浓度(OR 13.73,95%CI 3.31-57.07)和高密度脂蛋白胆固醇浓度(OR 1.49,95%CI 1.17-1.88)。
  • 与房颤检出风险降低相关的因素包括最小P波持续时间(OR 0.53,95%CI 0.29-0.98)、低密度脂蛋白胆固醇浓度(OR 0.73,95%CI 0.57-0.93)和甘油三酯浓度(OR 0.51,95%CI 0.41-0.64)。

关键数值与推荐

  • 年龄较大(OR 3.26,95%CI 2.35-4.54)、女性(OR 1.47,95%CI 1.23-1.77)、心衰史(OR 2.56,95%CI 1.87-3.49)、高血压(OR 1.42,95%CI 1.15-1.75)、缺血性心脏病(OR 1.80,95%CI 1.34-2.42)与房颤检出风险升高相关。
  • 较高改良Rankin量表评分(OR 6.13,95%CI 2.93-12.84)、较高NIHSS评分(OR 2.50,95%CI 1.64-3.81)、静脉溶栓(OR 2.40,95%CI 1.83-3.16)与房颤检出风险升高相关。
  • P波离散度(OR 7.79,95%CI 4.16-14.61)、脑钠肽浓度(OR 13.73,95%CI 3.31-57.07)、QTC间期(OR 3.68,95%CI 1.63-8.28)、最大P波持续时间(OR 3.19,95%CI 1.40-7.25)、PR间期(OR 2.32,95%CI 1.11-4.83)与房颤检出风险升高相关。
  • 低密度脂蛋白胆固醇浓度(OR 0.73,95%CI 0.57-0.93)、甘油三酯浓度(OR 0.51,95%CI 0.41-0.64)、最小P波持续时间(OR 0.53,95%CI 0.29-0.98)与房颤检出风险降低相关。

临床怎么用

  • 可利用年龄、合并症、卒中严重程度、P波指标及脑钠肽等标志物识别卒中后房颤高危患者,优化心脏监测选择。

局限性

  • 总体偏倚风险为中等。
  • 生物标志物的预后效用需以前瞻性研究评估,以房颤检出和卒中复发为结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: To identify clinical, ECG, and blood-based biomarkers associated with atrial fibrillation (AF) detection after ischaemic stroke or TIA that could help inform patient selection for cardiac monitoring. METHODS: We performed a systematic review and meta-analysis and searched electronic databases for cohort studies from January 15, 2000, to January 15, 2020. The outcome was AF ≥30 seconds within 1 year after ischemic stroke/TIA. We used random effects models to create summary estimates of risk. Risk of bias was assessed using the Quality in Prognostic Studies tool. RESULTS: We identified 8,503 studies, selected 34 studies, and assessed 69 variables (42 clinical, 20 ECG, and 7 blood-based biomarkers). The studies included 11,569 participants and AF was detected in 1,478 (12.8%). Overall, risk of bias was moderate. Variables associated with increased likelihood of AF detection are older age (odds ratio [OR] 3.26, 95% confidence interval [CI] 2.35-4.54), female sex (OR 1.47, 95% CI 1.23-1.77), a history of heart failure (OR 2.56, 95% CI 1.87-3.49), hypertension (OR 1.42, 95% CI 1.15-1.75) or ischemic heart disease (OR 1.80, 95% CI 1.34-2.42), higher modified Rankin Scale (OR 6.13, 95% CI 2.93-12.84) or National Institutes of Health Stroke Scale score (OR 2.50, 95% CI 1.64-3.81), no significant carotid/intracranial artery stenosis (OR 3.23, 95% CI 1.14-9.11), no tobacco use (OR 1.93, 95% CI 1.48-2.51), statin therapy (OR 2.07, 95% CI 1.14-3.73), stroke as index diagnosis (OR 1.59, 95% CI 1.17-2.18), systolic blood pressure (OR 1.61, 95% CI 1.16-2.22), IV thrombolysis treatment (OR 2.40, 95% CI 1.83-3.16), atrioventricular block (OR 2.12, 95% CI 1.08-4.17), left ventricular hypertrophy (OR 2.21, 95% CI 1.03-4.74), premature atrial contraction (OR 3.90, 95% CI 1.74-8.74), maximum P-wave duration (OR 3.19, 95% CI 1.40-7.25), PR interval (OR 2.32, 95% CI 1.11-4.83), P-wave dispersion (OR 7.79, 95% CI 4.16-14.61), P-wave index (OR 3.44, 95% CI 1.87-6.32), QTc interval (OR 3.68, 95% CI 1.63-8.28), brain natriuretic peptide (OR 13.73, 95% CI 3.31-57.07), and high-density lipoprotein cholesterol (OR 1.49, 95% CI 1.17-1.88) concentrations. Variables associated with reduced likelihood are minimum P-wave duration (OR 0.53, 95% CI 0.29-0.98), low-density lipoprotein cholesterol (OR 0.73, 95% CI 0.57-0.93), and triglyceride (OR 0.51, 95% CI 0.41-0.64) concentrations. DISCUSSION: We identified multimodal biomarkers that could help guide patient selection for cardiac monitoring after ischaemic stroke/TIA. Their prognostic utility should be prospectively assessed with AF detection and recurrent stroke as outcomes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cameron A, Cheng HK, Lee RP, et al. Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. Neurology. 2021. PMID: 34504030. doi:10.1212/WNL.0000000000012769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。